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Abstract Mucopolysaccharidosis type II (MPS II; Hunter
syndrome) is an X-linked, recessive, lysosomal storage
disorder caused by deficiency of iduronate-2-sulfatase. It
has multisystemic involvement, with manifestations in the
brain, upper respiratory tract, heart, abdomen, joints and
bones. Bone involvement leads to decreased growth
velocity and short stature in nearly all patients. A
therapeutic option for patients with MPS II is enzyme
replacement therapy (ERT) with idursulfase (Elaprase®).
We compared annual growth rates before and during ERT
in 18 patients from Mainz, Germany, and Manchester, UK.
Group 1 included nine patients who started ERT before
10 years of age; group 2 contained nine patients aged more
than 10 years at the start of ERT. All patients had received
weekly or biweekly ERT or placebo for 1 year, followed by
ERT for more than 3 years. For patients in group 1, the
mean (± SD) height increase was 14.6±5.5 cm during
3 years of ERT. Only one patient in this group (who was
below the 3rd percentile when starting ERT) deviated from
the normal growth curve over this time. Patients in group 2
had a mean height increase of 8.1±1.7 cm after 3 years of
ERT compared with an increase of 1 cm in the year before
ERT. ERT seems to have a positive influence on growth in
patients with MPS II. Most benefit is seen in patients
beginning ERT before the age of 10 years. This supports
the recommendation that ERT should be started as early as
possible in patients with MPS II.
Abbreviations
CDC US Centers for Disease Control
ERT Enzyme replacement therapy
GAGs Glycosaminoglycans
HRQoL Health-related quality of life
HOS Hunter Outcome Survey
MPS II Mucopolysaccharidosis type II
Introduction
Mucopolysaccharidosis type II (MPS II or Hunter syndrome;
OMIM 309900) is an X-linked recessive disease caused by a
deficiency of the lysosomal enzyme iduronate-2-sulfatase,
which catalyses the degradation of the glycosaminoglycans
(GAGs) dermatan sulfate and heparan sulphate (Neufeld and
Muenzer 2001). This enzyme deficiency leads to progressive
lysosomal storage of non-degraded GAGs in nearly all cell
types, tissues and organs. The phenotypic expression of
MPS II is thought to be due to the intracellular accumulation
of GAGs.
Phenotypic expression varies considerably. Clinically,
MPS II should be regarded as a continuum between the two
extreme forms of the disease (severe and attenuated).
Patients with severe MPS II may exhibit somatic involve-
ment between 2 and 4 years of age, with variable
progressive neurological involvement leading to mental
impairment. In these patients, death occurs in the first or
second decade of life, usually due to progressive neuro-
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and/or cardiac failure (Neufeld and Muenzer 2001).
Although the clinical course for the more severely affected
patients is relatively predictable, there is considerable vari-
ability in the clinical phenotype and progression of the
attenuated form of the disease. In patients with the attenuated
form of MPS II, there is minimal neurological involvement,
and patients can survive into young adulthood. They may,
however, present with mild-to-moderate learning difficulties
and often have symptoms and complications that cause
significant morbidity and disability. Both severely affected
individuals and those with attenuated disease have a range of
symptoms including short stature, dysostosis multiplex,
hearing impairment, enlarged tongue, abnormal dentition,
upper airway obstruction, hepatosplenomegaly and joint
contractures associated with a decreased range of joint
movement.
Infants with MPS II appear normal at birth, and early
developmental milestones may also be within the normal
range; in the first years of life the height of most patients
with MPS II is above the 50th percentile and in some cases
is over the 97th percentile. However, growth velocity
decreases with age: by the age of 8 years, height is below
the 3rd percentile (Schwartz et al. 2007), and nearly all
patients exhibit growth retardation before puberty [Hunter
Outcome Survey (HOS); unpublished data]. In a prospective
study of height in seven Brazilian patients followed-up over
1y e a r( P i n t oe ta l .2006), MPS II was associated with a
decreased growth velocity compared with year 2000
reference values from the US Centers for Disease Control
(CDC) (Kuczmarski et al. 2000).
Physical growth is an issue of paramount importance in
paediatric practice and a highly emotive issue for parents.
Individuals with short stature encounter many challenges in
daily life. In addition, patients with MPS II have serious
medical problems and their short stature may make life
even more strenuous. The fact that their appearance makes
them extremely visible in society puts an additional strain
on their lives and those of their parents (Hunter 1998;
Moneymaker 1989).
Enzyme replacement therapy (ERT) has been available
for patients with MPS II since August 2006 in the USA
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clinical trial, ERT with idursulfase (Elaprase®; Shire
HGT Pharmaceuticals, Cambridge, MA, USA) produced
statistically significant improvements in the primary compos-
ite end point—the sum of ranked changes in the 6-min
walking test distance and ranked changes in the percentage
predicted forced vital capacity—compared with placebo, in
patients with attenuated disease (Muenzer et al. 2006).
The effect of ERT on height in patients with MPS I has
been reported (Sifuentes et al. 2007). Mean height increased
from 139 cm (SD±19 cm) at baseline to 159 cm (SD±3 cm)
at year 6. For patients who started ERT before puberty the
mean gain in height was 33 cm. To date, no trial data have
been published that examine the effect of ERT on growth in
MPS II. The present retrospective analysis of patients
enrolled in a clinical trial aimed to assess the effect of ERT
on linear growth in patients with the attenuated phenotype of
MPS II.
Materials and methods
Patient population
Participants were recruited from the Metabolic Department
of the Mainz Children’s Hospital (Germany) and the Royal
Manchester Children’s Hospital (UK). All patients and/or
parents signed an informed consent form before the study.
The eligible patient population for this analysis consisted
of 18 patients: 10 from the Metabolic Department of the
Mainz Children’s Hospital and 8 from the Royal Manchester
Children’s Hospital. All patients had attenuated disease but
with variable organ involvement. No patients had cardiac
failure or were on nocturnal respiratory support. No patients
had cognitive impairment.
Male patients with a confirmed diagnosis of MPS II,
who had commenced ERT with idursulfase before the end
of puberty and who had received idursulfase for 3 years
were included in this analysis. All patients had previously
enrolled in a phase II/III clinical trial of ERT (Muenzer et al.
2006). Patients received ERT with idursulfase, 0.5 mg/kg,
either every week (n=5) or every other week (n=7), or
placebo (n=6) for the first year. After the first year, all
patients received idursulfase on a weekly basis. Patients on
long-term oral steroid treatment and those who had
previously received growth hormone therapy were excluded
from the analysis.
Height measurements were available at all time points
(the year before starting ERT, at baseline and at years 1,
2 and 3 on treatment) for 15 patients; complete data were
not available for 3 patients (2 patients for the year before
starting ERT and 1 patient for 3 years on ERT). Height
was measured using a stadiometer according to standard
protocols.
Statistical analysis
Two groups of patients were analysed according to their age
at the start of ERT (baseline): group 1 included patients
under 10 years of age (n=9); group 2 included patients over
10 years of age (n=9).
Height measurements were plotted against normal height
data for boys obtained from the CDC growth charts
(Kuczmarski et al. 2000). These charts were used as they
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(Muenzer et al. 2006). A Z score (the number of standard
deviations a particular value is from the mean) was
calculated for these height measurements and plotted in a
similar way.
For each age group, the mean changes in height and Z
score (± SD) from baseline were calculated. The velocity
and the yearly change in Z score were assessed from the
year before to 3 years after the start of ERT. For these
analyses, the population was restricted to patients with
available data for all time points (n=15).
The mean change in growth velocity (± SD) was
calculated for each time point from the year prior to
starting ERT.
Results
For the whole sample (n=18; age range at baseline, 6–
19 years), height was 108–154 cm (median, 126.5 cm); ten
of the patients (55.5%) were considered to be of short
stature, defined as having a height below the 3rd percentile
for age.
In group 1 (n=9; age range at baseline, 6–9 years) height
was 108–130 cm (median, 124 cm); only one boy was of
short stature. The mean increase in height over the 3-year
period of ERT was 14.6 cm (SD±5.5 cm). The growth
curves during ERT show that the height of eight of these
patients was still within the normal range based on CDC
growth charts (Kuczmarski et al. 2000); one patient was
more than 2 SD below the mean before starting treatment
(Figs. 1 and 2).
The Z scores calculated by year were –0.05±0.25 for the
first year, and –0.12±0.39 and –0.12±0.57 for the second and
third years, respectively. The growth velocity the year before
ERTand for 3 years on ERTwas calculated in seven patients.
This analysis reveals an increase in height of about 3 cm (Z
score=−0.5) the year before ERTand 5.3 cm (Z score=0.02),
4.5 cm (Z score=−0.07) and 5.7 cm (Z score=0.08) for the
first, second and third years on ERT respectively (Figs. 3
and 4).
In group 2, all nine patients were considered to be of short
stature (height range, 121–154 cm; median 130 cm). During
3 years of ERT the mean increase in height was 8.1±1.6 cm.
Growth charts and Z scores are shown in Figs. 5 and 6.
Yearlygrowthvelocitywascalculatedinallninepatientsin
group 2. The increase in height was 1.5 cm (Z score=−0.8) in
the year before ERTcompared with 3.9 cm (Z score=−0.17),
3.6cm(Zscore=0.23) and 1.3 cm (Z score=−0.06) for the
first, second and third years of ERT respectively (Figs. 7
and 8).
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Fig. 1 Growth charts for MPS II patients under 10 years of age at the
start of enzyme replacement therapy (ERT). The dotted lines illustrate
the growth before ERT and the continuous lines the growth on ERT.
The shaded area represents the 3rd to the 97th percentiles of height in
boys based on CDC growth charts (Kuczmarski et al. 2000)
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Fig. 2 Z scores for height in MPS II patients under 10 years of age at
the start of enzyme replacement therapy (ERT). The dotted lines
illustrate the scores before ERT and the continuous lines the scores on
ERT (based on CDC growth charts; Kuczmarski et al. 2000).
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Fig. 3 Yearly growth velocity for patients with MPS II under 10 years
of age at the start of enzyme replacement therapy (ERT)
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Short stature in MPS is linked to dysostosis multiplex.
Typical signs of this skeletal dysplasia are gibbus, scoliosis,
epiphyseal dysplasia and degenerative joint disease (Areu
et al. 1995). A follow-up study on patients with MPS I on
ERT for 6 years did not reveal any distinct changes in
dysostosis multiplex (Muenzer et al. 2006). We assume,
therefore, that ERT in patients with MPS II will also have
little or no effect on these symptoms. Histological exami-
nations of a biopsy from a Hurler syndrome patient or from
animal models with different types of MPS revealed
pathology of the growth plate possibly related to GAG
accumulation (Areu et al. 1995; Silveri et al. 1991; Russell
et al. 1998). Pathophysiological studies of the skeletal
manifestations of MPS II may also help to understand the
effects of ERT.
Although short stature is common to most types of MPS,
there are few published data on the effects of ERT on
growth in patients with other mucopolysaccharidoses, other
than one study in patients with MPS I (Sifuentes et al.
2007). In this report, we describe the first long-term
analysis of the effects of ERT on height in children with
MPS II. Height measurements were analysed within two
age-stratified cohorts. The age cut-off of 10 years was
selected because growth in patients with MPS II tends to
follow a normal trajectory until 8 years of age after which
growth is markedly reduced (Schwartz et al. 2007). Our
cohorts reflect this growth pattern; in group 1 (<10 years of
age at the start of ERT) only one of the nine patients was
considered to be of short stature compared with all nine
patients in group 2 (>10 years of age at the start of ERT).
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Fig. 7 Yearly growth velocity for MPS II patients over 10 years of
age at the start of enzyme replacement therapy (ERT)
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Fig. 6 Z scores for height in MPS II patients over 10 years of age at
the start of enzyme replacement therapy (ERT). The dotted lines
illustrate the scores before ERT and the continuous lines the scores on
ERT (based on CDC growth charts; Kuczmarski et al. 2000)
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Fig. 5 Growth chartsfor MPS II patientsover10yearsofageatthestart
ofenzymereplacementtherapy(ERT).Thedotted lines show the growth
before ERT and the continuous lines the growth on ERT. The shaded
area represents the 3rd to the 97th percentiles of height in boys based
on CDC growth charts (Kuczmarski et al. 2000)
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Fig. 4 Z scores for data in Fig. 3 (MPS II patients under 10 years of
age at the start of enzyme replacement therapy; ERT). A Z score of 0
means that height is at the mean value for the normal population. A
negative Z score means that height is below the 50th percentile
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before the age of 10 years. With one exception, the height
of boys in group 1 remained above –2 SD even beyond the
age of 10 years. The exception was a boy who was already
below –2 SD before starting treatment. His relatively poor
response may have been associated with the development
of antibodies that, in vitro, appear to have had some
neutralizing activity. Further studies, however, are needed
to determine the clinical significance of the development of
antibodies.
Theboysingroup2,whowereabove10yearsofageatthe
start of ERT, also showed an increase of growth velocity in
their first 2 years of ERTcompared with the year before ERT;
growth rate in the third year was similar to that in the year
before ERT. It is possible that this slower growth rate during
the third year of treatment is related to the completion of
puberty in these older boys. However, this cannot be
confirmed, as the stage of puberty was not documented in
this population. Also, patients with MPS II may have delayed
puberty. It is important to note that the height of two of the
boys in this group was above the 3rd percentile for age at the
start of treatment and that one of the patients was particularly
short, with a height Z score of approximately –7 at the start of
treatment.
The continued increase in height over 3 years, particu-
larly in the group aged under 10 years at the start of ERT,
almost certainly represents real growth and is not due to
patients standing straighter because of a reduction in joint
contractures. In fact, an increase in height can contribute to
joint contractures until the muscles and tendons adapt to the
new bone growth. Physiotherapy may be beneficial in this
respect, resulting in reduction of joint contractures and an
apparent increase in height.
A recent non-age-stratified analysis of data from HOS
revealed a similar growth acceleration in patients with MPS
II given ERT with idursulfase for at least 1 year (Beck et al.
2008). HOS is a multinational long-term outcomes survey
covering the natural history of Hunter syndrome and the
safety and effectiveness of ERT with idursulfase. Ongoing
collection of data in HOS, including analysis of the
response to ERT and pubertal development status, will
further elucidate the effect of ERT with idursulfase on
growth.
Studies into the effects of short stature and the response
to ERT are important as there is an assumption that short
stature may lead to psychosocial stress in childhood and
adolescence (Siegel et al. 1991), which may be at least
partially relieved by bringing height closer to the mean for
age. One study has shown a significant correlation between
adult short stature and health-related quality of life
(HRQoL), which suggests that increasing final height in
children with short stature may be beneficial and could
enhance HRQoL outcomes (Christensen et al. 2007).
There has been limited research on the psychological
and social effects of stature in patients with MPS II,
although one study reports significant psychosocial
problems in teenagers and young adults (Young and
Harper 1981). For young adults with short stature due to
growth hormone deficiency, childhood onset of renal
failure or Turner syndrome, the opportunity for having a
partner was low (Busschbach et al. 1998). Young adults
with MPS II in our clinics also report problems in finding
a partner.
It is unwise, however, to extrapolate the findings from
general research into the effects of short stature. Individuals
with MPS II have dysmorphism, pain and other medical
complications and so might encounter very different
psychosocial and HRQoL problems than those with other
causes of short stature. Nevertheless, as in many similar
diseases, short stature serves as a distinguishing character-
istic for MPS II. An increase of height towards normal
would remove one of the most visible features of the
disease, which may have a positive impact on both the
patients and their parents.
Conclusions
MPS II is a severe progressive multisystemic disorder that
has the potential to cause disease in most body systems and
is associated with small stature. ERT has been shown to be
effective in treating many of the manifestations of MPS II,
especially if started early in the course of the disease. The
present data show that ERT with idursulfase also has a
positive effect on growth velocity in patients with MPS II.
The effect is more obvious in patients who started ERT
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Fig. 8 Z score for data in Fig. 7 (MPS II patients over 10 years of age
at the start of enzyme replacement therapy; ERT). A Z score of 0
means that height is at the mean value for the normal population. A
negative Z score means that height is below the 50th percentile
J Inherit Metab Dis (2011) 34:203–208 207before the age of 10 years. This is the first published report of
the impact of ERT on growth in young patients with Hunter
syndrome.Furtheranalysesinlargergroupsofpatientswillbe
needed to add to these findings.
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